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Objective: To describe the methodological challenges and decisions made in developing a 
multisite, controlled study of risperidone in children and adolescents with autism. 
Methods: Review the design considerations for clinical trials in children with autistic disorder 
accompanied by severe tantrums, aggressive and/or self-injurious behaviors. These design considerations 
include the definition of inclusion criteria that are relevant to clinical practice and matching study design to 
the goal of evaluating short- and long-term effects. Additional ethical and scientific issues concern the 
length of trial and sample size. 
Results: We undertook a short-term, placebo-controlled study to evaluate the efficacy and safety 
of risperidone in children and adolescents with autistic disorder. This trial design was followed by an 
extended open-label maintenance on risperidone to confirm durability of treatment effects and to monitor 
safety. Finally, a placebo-controlled discontinuation study tested the need for continuous treatment. 
Conclusions: In the absence of standard pharmacological treatment for children with autistic 
disorder, a placebo-controlled study remains the most appropriate method of testing efficacy and safety. 
The clinical relevance of this study is enhanced by the addition of an extended maintenance phase followed 
by a placebo discontinuation. 
Introduction 
Autistic disorder is a chronic condition of early childhood onset characterized by 
profound impairments in social relatedness, communication skills, and restricted patterns of 
behavior 
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b = random assignment to continued treatment with risperidone or gradual placebo substitution; 
c = continued observation or treatment as appropriate; 
d = uses same dose and visit schedule as in double-blind phase. 
The study was divided into three phases designed to evaluate the short- and long-term 
safety and efficacy of risperidone in children and adolescents with autistic disorder. Phase 1 was 
an 8-week, double-blind, randomized, parallel-groups comparison of risperidone and placebo. 
Subjects assigned to placebo who did not improve were offered an 8-week open-label trial of 
risperidone. Phase 2 consisted of a 4-month open-label treatment with risperidone for patients 
who showed improvement in the 8-week acute trial. The subsequent phase 3 was a randomized, 
double-blind, placebo-controlled discontinuation study (see Fig. 1). The target symptoms 
included tantrums, aggression, SIB, agitation, screaming, emotional rigidity, and repetitive 
behavior as measured by the Irritability subscale of the Aberrant Behavior Checklist completed 
by the parent or primary caretaker (Aman and Singh 1986; Aman et al. 1985; Mashburn and 
Arman 1992). This subscale was selected because of its favorable psychometric properties 
(Mashburn and Aman 1992), and it contains the behaviors of interest. To avoid overreliance on 
an informant-based measure, the study also included clinician and laboratory measures as 
secondary outcomes (for a detailed description of assessment measures used in the study, see 
Arnold et al. 2000). The rationale for choosing risperidone was based on concern about the short- 
and long-term side effects of haloperidol (Campbell et al. 1997) and emerging pilot data from 
several centers showing encouraging results with risperidone (see McDougle et al. 2000 for a 
detailed review). This article describes the methodological issues encountered and the design 
decisions taken in developing the multisite clinical trial of risperidone by the RUPP Autism 
Network. 
Short-Term Safety and Efficacy 
The primary purpose of the first phase of the study was to compare the short-term safety 
and efficacy of risperidone and placebo in the treatment of children and adolescents with autistic 
disorder. We hypothesized that risperidone would be more effective than placebo in reducing 
impulsive aggression, tantrums, SIB, screaming, and out-of-control behavior associated with 
autistic disorder. Important exploratory questions of interest included whether risperidone (a) 
would be more effective than placebo for improving repetitive behavior in children and 
adolescents with autistic disorder; (b) would be associated with extrapyramidal side effects; (c) 
would be associated with specific side effects such as excessive weight gain or prolactinemia; 
and (d) whether specific CYP450 2D6 genotypes would be associated with clinical response, a 
range of adverse effects, and/or higher steady-state levels of risperidone. 
Placebo control 
The rationale for placebo control was based on the intent to evaluate safety and efficacy. 
First, placebo response has been observed in serious disorders such as autism (Sandler et al. 
1999). Second, the only medication that could be proposed as a standard treatment for aggression 
and SIB in children with autistic disorder is haloperidol (Anderson et al. 1989). However, 
clinicians and families often avoid using this medication due to legitimate concerns about short- 
and long-term side effects (Campbell et al. 1977; McDougle et al. 2000). A direct comparison of 
risperidone or haloperidol was discarded as clinically unacceptable. Behavior modification 
treatment was not considered a reasonable comparison either, because it is often tried before 
pharmacotherapy and it would be difficult to ensure blinding in the study. In the absence of a 
satisfactory standard treatment, therefore, placebo control was fully justified. 
Placebo control was also justified because autism is a chronic condition, and treatment of 
associated behavioral symptoms often requires pharmacotherapy for long periods of time. It is 
therefore important to provide clear-cut evidence of medication efficacy and safety in order to 
validate extended use. A placebo-controlled trial is the most efficient method of testing treatment 
effects. Moreover, the placebo control group provides a contrast group for assessment of adverse 
events. The decision to conduct an 8-week trial was a compromise between the amount of time 
required to show a treatment effect and our interest in avoiding a prolonged period without active 
treatment for subjects randomly assigned to placebo. To minimize the potential burden of 
placebo assignment, subjects who were randomized to placebo and failed to show a clinically 
meaningful response (placebo nonresponders) were eligible to participate in an 8-week open-
label trial of risperidone after a minimum of 4 weeks in the double-blind phase (see Fig. 1). The 
8-week, open-label trial mimicked the double-blind treatment with respect to dose schedule, 
frequency of follow-up visits, and outcome measurement. 
Sample selection 
Tables 1 and 2 present the inclusion and exclusion criteria used in the study. Selection of 
these criteria was guided by the goal of producing generalizable results. For example, 25% to 
33% of children with autism also have seizures (Cohen and Volkmar 1997). If risperidone proves 
to be safe and effective in autism, children on anticonvulsants are likely to be treated with 
risperidone. Failure to include subjects on anticonvulsants would have limited the clinical 
application of the study findings. On the other hand, changes in anticonvulsant dose during the 
study could have had an impact on the child’s behavior and/or the interpretation of adverse 
effects. Thus, this entry criterion was qualified by insisting that both the dose of medication and 
the seizure disorder were stable prior to entry. 
The decision to include only subjects diagnosed with autism was based on the presumed 
greater variability in response if a wider range of PDD subjects was included in the study. 
Although autism is unlikely to be a homogeneous disorder, the inclusion of children with other 
forms of PDD in the study invited undue heterogeneity. Within the diagnostic category of 
autism, however, we attempted to maximize generalizability by including subjects across a wide 
range of IQ. Children below a mental age of 18 months were excluded because of the 
fundamental problem of making the diagnosis of autistic disorder in profoundly retarded children 
(Lord et al. 1994). 
The decision to include only children diagnosed with autistic disorder had two important 
implications. First, the prevalence of autistic disorder is 5 to 20 cases per 10,000 compared to 10 
to 40 cases per 10,000 for other forms of PDD (Fombonne 1999; Chakrabarti and Fombonne 
2001). Thus, restricting study participation to subjects with autism accompanied by severe 
behavioral dyscontrol reduced the pool of eligible subjects. Second, although each site had 
investigators with expertise in the assessment and treatment of autism, the decision to include 
subjects with autism required a network-wide training on the administration of the Autism 
Diagnostic Interview–Revised to ensure reliability in the diagnosis. 
Randomization and dose schedule 
To make certain that treatment groups would be comparable, the randomization was 
balanced within site by pubertal status (Tanner stages I and II for prepubertal status and Tanner 
III or higher for postpubertal status), gender, and anticonvulsant use. The medication schedule 
was based on the subject’s weight. Children weighing at least 20 kg at study entry were started at 
a dose of 0.5 mg at bedtime. As shown in Table 3 (top half), the dose was increased to 0.5 mg 
twice daily at day 4 and gradually thereafter to a maximum of 2.5 mg per day (1.0 mg in the 
morning and 1.5 mg at bedtime) by day 29. A similar but slightly faster dose schedule was used 
for children weighing 45 kg or more (maximum of 1.5 mg in the morning and 2.0 mg at bedtime) 
as is shown in Table 3 (bottom half). For children with baseline weight between 15 and 20 kg, 
the starting dose was 0.25 mg/day. 
 Males and females between the ages of 5 years and 17 years 2 months 
 DSM-IV diagnosis of autistic disorder (established by clinical assessment, corroborated by the Autism 
Diagnostic Interview) 
 Inpatients or outpatients 
 Medication free for at least 2 weeks for all psychotropic medications (4 weeks for fluoxetine or depot 
neuroleptics) 
 Anticonvulsants used for the treatment of a seizure disorder were permitted if the dosage had been stable 
for 4 weeks and the patient had been seizure free for at least 6 months. 
 Clinical Global Impressions severity score of at least 4 (moderately ill) at baseline rated by the blinded rater 
 A score of 18 or greater on the Irritability subscale of the Aberrant Behavior Checklist at baseline (on the 
parent-rated and/or clinician-rated version) 
 A mental age of at least 18 months as measured by the age-appropriate form of the Wechsler Intelligence 
Test, by the revised Leiter, or by the Mullen 
Table 1. Inclusion Criteria for Double-Blind Risperidone Study in Children and Adolescents with Autism 
 Females with a positive Beta human chorionic gonadotropin (HCG) pregnancy test 
 Evidence of a prior adequate trial with risperidone (defined as duration of 2 weeks or more at a dose of at 
least 1 mg/day) 
 Evidence of hypersensitivity to risperidone (defined as allergic response [e.g., skin rash] or potentially 
serious adverse effect [e.g., significant tachycardia]) 
 Past history of neuroleptic malignant syndrome 
 DSM-IV diagnosis of schizophrenia, another psychotic disorder, or substance abuse 
 A significant medical condition such as heart disease, hypertension, liver or renal failure, or pulmonary 
disease identified by history, physical examination, or laboratory tests 
 Weight less than 15 kg 
Table 2. Exclusion Criteria for Double-Blind Risperidone Study 
In all cases, the dose schedule was not fixed. The decision to increase the dose above 1 
mg/day was based on clinical judgment. For example, in the presence of a positive clinical 
response as evidenced by a rating of much improved or very much improved on the Global 
Improvement item of the Clinician’s Global Impressions (CGI) scale or clinically important side 
effects (e.g., sedation), the dosage was not automatically increased. If a symptomatic 
deterioration was evident at a subsequent visit, or if the dose-limiting side effect resolved, the 
clinical team was free to resume upward dose adjustment. In the double-blind trial, there were no 
dose increases allowed after day 29. After day 29, the dose was maintained until the endpoint 
(day 56), unless adverse effects emerged at which point the primary clinician could lower the 
dose of the medication. Finally, the clinical team was permitted to prescribe benztropine to 
manage extrapyramidal symptoms. 
Model dose schedule for subjects between 20 and 45 kg 
Study day Morning dose (mg) 
Bedtime dose 
(mg) 
1 __ 0.5 
4 0.5 0.5 
8 0.5 1.0 
16 1.0 1.0 
22 1.0 1.5 
29a 1.0 1.5 
Dose schedule for subjects ≥45 kg 
1 __ 0.5 
4 0.5 0.5 
8 0.5 1.0 
12 1.0 1.0 
15 1.0 1.5 
18 1.5 1.5 
23 1.5 2.0 
29a 1.5 2.0 
Table 3. Dose Schedule 
aVisit on day 29 was last point to authorize a dose increase; dose reduction to manage side effects can be 
done at any time. 
Compliance. 
Parents were given a diary card at each visit with day-by-day instructions about the 
medication dose. Compliance was monitored by pill counts and by review of the diary card at 
each visit. Any deviation from the prescribed dose was discussed in order to ensure an optimal 
dosing strategy. If the compliance fell below 70% of the prescribed dosage for a given week via 
pill count, parents were educated about the importance of taking the medication as prescribed. 
Continued deviation from the prescribed dosing regimen, in the absence of extenuating 
circumstances, would lead to the subject’s termination from the study. Due to the predictable 
difficulties of drawing blood samples from this nonverbal, often aggressive population, we did 
not include the measurement of plasma drug level determinations as an additional method of 
discerning compliance during the study. The drug level drawn at endpoint, which was coincident 
with blood sampling for laboratory tests, permitted a check on compliance and an examination of 
the relationship between CYP 2D6 genotype, blood level, and clinical response. 
Ensuring blindness and breaking the blind 
The blind in a placebo-controlled study may be compromised by the emergence of 
obvious side effects. Therefore, each subject was followed by two clinicians: a blinded clinical 
evaluator, who focused on clinical ratings, and a blinded primary clinician, who evaluated side 
effects and adjusted the medication dosage. At the end of the double-blind phase, but before the 
treatment code was broken, each subject was classified as a responder or nonresponder. Positive 
treatment response was defined by a decrease of 25% on the Irritability subscale of the Aberrant 
Behavior Checklist and a rating of much improved or very much improved on the Global 
Improvement item on the CGI at endpoint. Once this determination was made, the primary 
clinician broke the treatment code and initiated the next step in the subject’s treatment. The 
rationale for breaking the blind was to ensure continuity of care for subjects who benefited from 
the active medication during the double-blind phase and to evaluate subsequent clinical response 
to open-label treatment for placebo nonresponders in the double-blind phase. 
At the end of the double-blind phase, subjects were cross-classified by treatment 
assignment and clinical response (risperidone responder, risperidone nonresponder, placebo 
nonresponder, or placebo responder). Risperidone responders were invited to participate in the 4-
month extension study (Fig. 1). These subjects were seen monthly for 4 months (see description 
of phase 2 below). Although visits were scheduled on a monthly basis, interim visits with the 
primary clinician were scheduled on an as needed basis. 
Placebo nonresponders entered an 8-week, open-label risperidone trial, which mimicked 
the double-blind study with respect to weekly visits and dose schedule. These subjects were seen 
weekly for the first 4 weeks by the primary clinician to monitor side effects and adjust the 
dosage. The blinded clinical evaluator did not resume clinical ratings until the end of the first 
month in the open-label phase. This plan ensured continuity in that the same blinded clinical 
evaluator conducted outcome measures. It also provided some additional protection of the blind 
in that the blinded clinical evaluator remained unaware of treatment assignment during the 
double-blind study. Subjects who were judged to be responders after 8 weeks of open-label 
treatment were invited to enroll in the 4-month extension (phase 2) followed by the placebo-
controlled discontinuation phase. 
Risperidone nonresponders were treated in accordance with the best judgment of the 
clinical team and the family’s preference. Similarly, responders to placebo in the double-blind 
phase were not invited into the 8-week open-label study (Fig. 1). These subjects were followed 
by the clinical team, and treatment decisions were based on the subject’s clinical picture. 
Data analytic plan for primary hypothesis in phase 1 
Sample size. 
The sample size of 100 was chosen to ensure sufficient power to detect a moderate 
treatment difference between risperidone and placebo. Based on conservative estimates, such as 
a positive response of 40% for the risperidone group and 10% for the placebo group, the power 
to detect a difference between treatments is 94% with 50 in each group. Even if the difference in 
the rate of positive response is only 25%, the power to detect that difference between groups 
would be 86% at the conventional 5% level of significance (Borenstein et al. 1997). The sample 
size of 100 was also intended to identify differences in the frequency of common adverse events 
across the two treatments. Adverse events with an expected frequency of 6% or larger are 
detectable with the projected sample size of 50 in each group with a power of 95%, whereas a 
frequency of 3% or larger is detectable with a power of 78%. 
Evaluation of efficacy. 
The intent-to-treat principle in which all randomized subjects are included in the analyses 
will guide the evaluation of efficacy (Fleiss 1986). The primary outcome measure, the Irritability 
subscale of the Aberrant Behavior Checklist (completed by the parent), will be analyzed with a 
mixed effects linear model, also called a random regression model (Gibbons et al. 1993). In this 
approach, each subject’s response during the trial is modeled by regressing the response against 
time. The intercept and slope of the regression are estimated for each subject. A subject who 
shows a strongly positive response over time will have a much larger regression slope than a 
subject who barely changes over time. The average slope of the regression of response on time is 
compared across the risperidone and placebo groups and tested for statistical significance. An 
obvious advantage of the mixed model is that it permits a careful look at individual responses as 
well as group effects. 
Another advantage of the mixed model is that it is more tolerant of missing data than 
repeated-measures analysis of variance, which only uses those subjects who have complete data. 
Analyses of data from only those subjects who complete the protocol may be biased by factors 
related to attrition. By contrast, subjects who terminate the protocol prematurely can be included 
in the mixed model. The random regression model can estimate change parameters as long as 
there are at least two observations over time. 
A more straightforward and clinically relevant approach to evaluating the efficacy of 
risperidone is to calculate the difference in the rate of positive response between the two 
treatment groups. By using the definition of positive response described above, we will also 
compare the rate of positive response in each treatment group by a chi-square test. This 
computation will provide clinicians with an estimate of how likely a patient with similar 
problems will respond to treatment with risperidone. 
Evaluation of safety. 
Adverse events were systematically assessed and recorded at each visit by the primary 
clinician. Height, weight, vital signs, and concomitant medications were also documented at each 
weekly visit. An electrocardiogram and routine laboratory studies were conducted at the baseline 
and final visit in the double-blind phase (Kumra et al. 1997). Because our interest was in 
documenting any changes in cardiac conduction, electrocardiograms were read by pediatric 
cardiologists at all sites. Laboratory measures included complete blood count, electrolytes, blood 
urea nitrogen, creatinine, liver function tests, and urinalysis. Electroencephalograms were not 
done. 
Differences in rates of adverse events between the risperidone and placebo groups will be 
tested by chi-square with Fisher’s exact test when cell sizes are less than 5. Other analytic 
approaches will compare counts of adverse events in each of the two treatment groups using t 
tests. 
Cytochrome P450 2D6 (CYP2D6) enzyme genotype and clinical response. 
Risperidone is well absorbed orally and has an estimated 4-hour half-life in adults. The 
major metabolic pathway is oxidation via the CYP2D6 pathway (Heykants et al. 1994). The 
major metabolite, 9-hydroxyrisperidone, appears to be equally potent as risperidone with respect 
to receptor binding activity. However, it has a 17-hour half-life and is not dependent on 
CYP2D6. 
Recent studies indicate that 5% to 10% of the Caucasian population and 2% to 6% of the 
African American population have little or no activity of the CYP2D6 enzyme (He et al. 1999; 
Poolsup et al. 2000). This lack of CYP2D6 activity is inherited as an autosomal recessive trait 
(homozygous for the low activity allele). By contrast, a small percentage of the population are 
ultrarapid metabolizers of CYP2D6 substrates due to gene amplification of the normal allele. To 
date, no studies have examined the relationship of CYP2D6 genotypes to risperidone level or 
clinical response in children and adolescents. By design, the dose of risperidone in children and 
adolescents in this study was constrained to fall in a narrow range (roughly 1.5 mg to 3.5 mg per 
day in divided doses). Despite this narrow range, we plan to evaluate the relationship between 
serum drug level, clinical response, and 2D6 genotype. The first set of exploratory analyses will 
examine the correlation of 2D6 genotype and blood level (adjusted for oral dose and body 
weight). 
Given that 9-hydroxyrisperidone is not dependent on CYP2D6, individuals with low 
activity of CYP2D6 are likely to show a higher ratio of the parent compound to the active 
metabolite. Nonetheless, the combined level may be similar at equivalent doses. This ratio of 
parent compound to metabolite may be associated with different clinical responses. If true, this 
could have important clinical implications. We predict that the genotypes associated with little or 
no activity of the CYP2D6 enzyme will show the highest drug level of the parent compound 
(corrected for mg/kg). Additional exploratory analyses will include whether the trough level of 
the parent compound, the active metabolite, or the combination are associated with positive 
response or specific side effects such as sedation and/or weight gain. 
Four-Month Extension Study 
Several recent reviews have noted the limits of current knowledge regarding the impact 
of long-term drug exposure on the developing brain (Vitiello 1998) and the paucity of data on the 
effectiveness of pharmacotherapy in children beyond short-term trials (Vitiello and Jensen 1997). 
Results from recent case-control studies with risperidone suggest that adverse effects, such as 
weight gain, may not be evident in a short-term course of treatment (Kelly et al. 1998; Martin et 
al. 2000). Thus, the primary aims of the 4-month extension phase were to determine whether the 
therapeutic gains achieved in the short term were stable and whether adverse effects emerged or 
intensified over time. To meet these goals, children and adolescents classified as responders to 
risperidone in phase 1 (the double-blind phase or the 8-week open-label study for the placebo 
nonresponders) were invited to participate in the 4-month, open-label extension phase. The 
prospective design of the extension protocol permitted evaluation of both continued benefit and 
the emergence of new side effects in a systematic fashion. If risperidone demonstrated 
superiority to placebo in the short term as well as enduring benefit over the additional 4-month 
observation period without the emergence of clinically meaningful adverse effects, it would be 
an important addition to the available treatments of children and adolescents with autism and 
related disorders. 
Double-Blind Placebo-Controlled Withdrawal 
Subjects who showed a positive response to risperidone through the 4-month extension 
phase were randomly assigned to continue active medication at the same maintenance dose or to 
gradual withdrawal to placebo over a 3-week period. The rate of medication withdrawal was 
roughly 25% per week. The maximum observation period in this final phase of the study was 8 
weeks. Because withdrawal from active medication could result in relapse prior to the end of the 
planned observation, this design decision raised an important ethical concern that had to be 
balanced with scientific and clinical considerations. 
First, we had to define relapse. Specific criteria for relapse were enumerated such that the 
return of target symptoms constituted treatment failure and marked the end of the discontinuation 
phase for that subject. Treating relapse as a discrete event permitted the use of clinically relevant 
statistical techniques that evaluate both the rate and time to relapse in each treatment group (see 
Analytic section below). This design feature also ensured that the placebo-controlled withdrawal 
period would not be prolonged to the full 8 weeks in the case of symptomatic relapse. Using the 
scores at randomization into the blinded discontinuation trial as baseline, relapse was defined as 
follows: a 25% or greater increase on the Irritability subscale of the Aberrant Behavior Checklist 
and two consecutive ratings by the blinded clinical evaluator of much worse or very much worse 
on the Global Improvement item of the CGI. 
Second, although risperidone appears to have a better side effect profile than halperidol, 
the types and severity of adverse effects in children and adolescents have not been well 
documented. Moreover, virtually nothing is known about withdrawal effects such as dyskinesias, 
which have been shown to be common with haloperidol (Campbell et al. 1997). Thus, it was 
important to determine whether such withdrawal effects would also be present after treatment 
with risperidone. Given the chronic nature of autism and related disorders, this information 
should assist clinicians and families in making informed decisions about the risks and benefits of 
risperidone treatment. If subjects randomized to placebo substitution manifested relapse without 
emergence of dyskinesias, this would provide further evidence for the effectiveness of 
risperidone in this population. 
Third, although autism is a chronic disorder, the symptom picture may change. New 
patterns of behavior may emerge over time. Thus, relapse was not a certainty. If subjects 
randomized to placebo substitution showed a return of target symptoms, long-term treatment 
with risperidone may be justified. On the other hand, if relapse did not occur, this would suggest 
that patients need not be exposed to a potent pharmacological agent beyond 6 months of 
treatment. 
Fourth, drug withdrawal is common in clinical practice. Even in serious disorders such as 
autism, parents and/or clinicians may wonder if the target symptoms that prompted drug 
treatment are still present and often elect to discontinue the drug. Thus, the placebo-controlled 
withdrawal phase mimics clinical practice. A potentially important difference between clinical 
practice and the placebo-controlled withdrawal study is that subjects were carefully monitored 
during the withdrawal, providing the opportunity to produce generalizable data about withdrawal 
effects. 
Fifth, if the target symptoms did return in the placebo substitution phase, we presumed 
that symptomatic control could be recaptured upon reinitiating active treatment. Furthermore, 
there is no evidence that, if relapse occurs in the short term during placebo substitution, the 
course of autism will be altered or worsened in the long term. 
Analytic plan and stopping rule for placebo discontinuation phase 
Relapse is the event of primary interest. Thus, the primary analytic strategy is to compare 
the rate of relapse in each group using a chi-square statistic (Fleiss 1986). Time to relapse will be 
evaluated for the risperidone and placebo groups by using Kaplan-Meier survival curves (log-
rank test). Other planned secondary analyses include the other subscales of the Aberrant 
Behavior Checklist, the Simpson-Angus scale, and the Abnormal Involuntary Movement Scale. 
Differences between the risperidone and placebo groups can be evaluated using standard linear 
statistical models. 
In addition to the stopping rule for individual subjects who relapsed, we also developed a 
stopping rule for the entire discontinuation phase of the study. The stopping rule for this phase of 
the study was based on a simple statistical test: if the rate of relapse in the placebo group versus 
the active treatment group reached significance (defined as power of 80% and p < 0.01) in the 
planned interim analyses, the discontinuation phase of the study would be stopped. These interim 
analyses were planned when the sample size reached 16 (8 per group) and 32 (16 per group)—
roughly equivalent to one third and two thirds of the expected total sample, respectively. Table 4 
presents a range of values comparing the proportion of relapse across sample sizes. 
Use of concomitant medications 
To be eligible for the study, subjects had to be free of psychotropic medication for at least 
2 weeks (4 weeks in the case of depot neuroleptics or fluoxetine). Anticonvulsant medications 
used for seizure control were permitted if the dose had been stable for 1 month and the subject 
had been seizure free for 6 months. We also needed a policy to manage subjects on stable doses 
of nonpsychotropic medication prior to entry. Moreover, given the long-term nature of the study, 
the likelihood that study participants would need concomitant medications for routine 
intercurrent illness or recrudescence of mild chronic conditions was predictably high. 
Concomitant medications taken during the study could have pharmacokinetic interaction with 
risperidone (e.g., absorption or hepatic metabolism) and/or pharmacodynamic interaction (e.g., 
effects on central dopaminergic systems). Thus, when describing the purpose and design of the 
study to subjects and their families, investigators emphasized the importance of reviewing all 
ongoing or proposed medication with the research team. 
To guide the use of concomitant medications during the study, we classified common 
pediatric medications as acceptable, drugs to avoid, and drugs considered unacceptable. The 
rationale for these recommendations was to prevent drug interactions that might pose a safety 
hazard, cause additive side effects, or confound the interpretation of behavioral response to the 
study medication. For example, because erythromycin or ceterazine can increase the QT interval 
(although presumably rare, this has also been reported for risperidone), these drugs were 
classified as unacceptable. Antihistamines, which may have sedative side effects, and 
metoclopromide, which may cause akathisia, were also considered unacceptable. The 
decongestant, pseudoephedrine, which may produce hyperactivity in some children, was 
classified as a medication to avoid. Also considered were drugs that may have an impact on 
risperidone concentration (e.g., tetracycline may induce CYP 2D6, which presumably would 
lower risperidone level). 
Sample size 
(per group) 
Relapse-placebo Relapse-active 
Powera 
α = 0.01 n (%) n (%) 
16 (8) 6 (75) 1 (12.5) 0.47 
16 (8) 7 (87.5) 1 (12.5) 0.74 
16 (8) 8 (100) 2 (25) 0.77 
16 (8) 8 (100) 1 (12.5) 0.97b 
32(16) 10 (62.5) 2 (12.5) 0.66 
32(16) 10 (62.5) 1 (6.7) 0.82b 
32(16) 12 (75) 2 (12.5) 0.90b 
32(16) 13 (81.3) 3 (18.8) 0.89b 
32(16) 14 (87.5) 5 (31.3) 0.79b 
32(16) 15 (93.8) 6 (37.5) 0.83b 
50 (25) 15 (60) 4 (16) 0.76 
50 (25) 15 (60) 3 (12) 0.87 
50 (25) 16 (64) 4 (16) 0.85 
50 (25) 18 (72) 6 (24) 0.83 
50 (25) 20 (80) 8 (32) 0.83 
50 (25) 22 (88) 9 (36) 0.92 
Table 4. Power Calculations for Detecting a Significant Difference in the Proportion of Relapse in 
Maintenance treatment Group Versus Placebo Substitution Group Across a Range of Sample Sizes 
aCalculated with Borenstein et al. (1997) Power Precision program; percentages are rounded to 1 
decimal place (e.g., 18.75 = 18.8). 
bRepresents scenarios for meeting stopping rule. 
These recommendations were organized into a list for investigators and a list for families. 
These lists were not exhaustive, but they contained specific recommendations about common 
medications, including over-the-counter remedies. Investigators were encouraged to consult with 
the subject’s pediatrician about medications that were not on the list. Medication questions were 
also reviewed on the weekly investigator conference calls. (Copies of the Concomitant 
Medication guide for investigators and the handout for parents are available upon request to 
Larry Scahill.) 
Consent and Other Ethical Issues 
The inclusion of nonverbal, often mentally retarded subjects in the study had important 
implications for the informed consent and assent procedures. For example, the placebo-
controlled design raised questions about competence to provide consent. Current guidelines from 
the Department of Health and Human Services indicate that consent is a legal concept involving 
the capacity to make decisions about one’s own life. This legal capacity begins at the age of 
majority (18 years of age in most states) and, in ordinary circumstances, cannot be delegated to 
others. When a parent gives permission for a minor, it is deemed “proxy consent.” In such cases, 
assent is obtained to indicate affirmation by the minor. If the minor is not capable of giving 
assent, parents can give permission for participation in research that confers direct benefit to the 
child or poses only minimal risk. If the person is not competent to consent after reaching the age 
of majority, a guardian is needed to give permission for participation in research. Although 
guardianship laws vary from state to state, a subject who turns 18 during the protocol could be in 
an uncertain status with respect to granting informed consent. To avoid this uncertainty, we 
decided to exclude adolescents older than 17 years 2 months to ensure that no subject would turn 
18 during the protocol. 
Another ethical consideration is that children with autistic disorder accompanied by 
aggressive and/or SIB would likely be on medication prior to study entry. For patients deriving 
partial benefit from medication prior to starting the study, there was a potential for worsening of 
target symptoms during the required 2- to 4-week washout period. This matter had to be 
discussed in detail with parents and required close monitoring during the withdrawal period prior 
to randomization. In keeping with the fundamental ethical principle of beneficence, no subject 
could be withdrawn from a currently effective medication. Finally, given the complexity of the 
study design, we evaluated parental impressions of the consent procedures in a 17-item 
questionnaire developed for the study. 
Clinical implications 
Autistic disorder is a severe developmental disorder of early childhood onset that can be 
accompanied by behavioral problems such as tantrums, SIB, aggression, and agitation. Although 
several medications are used in the treatment of children and adolescents with autistic disorder, 
there is no commonly accepted standard treatment. Therefore, treatment focuses on target 
symptoms that may be amenable to pharmacological intervention. The RUPP autism study (with 
the initial double-blind, placebo-controlled phase, the open-label extension phase followed by 
the placebo-substitution phase) was designed to evaluate short-term efficacy and safety as well 
as the long-term stability and safety of risperidone for aggression, SIB, and/or agitation that is 
consistent with this clinical model. The results of the study are likely to provide guidance to 
clinicians and families on the use of risperidone in the treatment of children and adolescents with 
autistic disorder and these target symptoms. 
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